Incidence of major complications (% pt-yr) | ||||||||||
---|---|---|---|---|---|---|---|---|---|---|
Author | Year | Drug | N | Mean age (years) | Total follow-up (pt-ys) | Mean follow-up (years) | Haemorrhagic | Thrombotic | Totalb | Mortality |
PSM of VKA | ||||||||||
Nagler [8]b | 2014 | VKA | 451 | 48.5 | 1939a | 4.3a | 0.9 | 0.5 | 1.4a | 1.1 |
Larsen [10] | 2016 | VKA | 444 | 46.6 | 1953 | 6.9 | 0.4 | 1.3 | 1.7a | 0.5 |
Our study | 2018 | VKA | 213 | 47.5 | 1288 | 6.0 | 0.2 | 0.6 | 0.9 | 0.4 |
Conventional management of VKA in highly specialized centres | ||||||||||
Wieloch [23] | 2011 | VKA | 1146 | 66 | 802 | 0.7a | 2.6 | 1.8 | 4.4a | NR |
Sjöegren [24] | 2015 | VKA | 17,219 | 65.3 | 48213a | 2.8a | 2.0 | 1.1 | 3.1a | NR |
Larsen [10] | 2016 | VKA | 2220 | 46.8 | 9569 | 6.7 | 0.4 | 2.2 | 2.6a | 1.1 |
Conventional management of VKA | ||||||||||
Ageno [44] | 2016 | VKA | 2149 | 66.0 | 1719a | 0.8a | 2.3 | 2.6 | 4.9a | 4.1 |
Sindet-Pedersen [45] | 2017 | VKA | 6907 | 66 | 3453a | 0.5 | 2.1 | 3.1 | 5.2a | NR |
Coleman [46] | 2017 | VKA | 32,244 | 43% > 60 | 16122a | 0.5 | 1.0 | 3.5 | 4.5a | NR |
Weycker [47] | 2018 | VKA | 17,878 | 60 | 7437a | 0.4 | 5.5 | 7.0 | 12.5a | NR |
DOACs | ||||||||||
Ageno [44] | 2016 | Rivaroxaban | 2619 | 59.0 | 1833a | 0.7a | 0.7 | 1.4 | 2.1a | 0.5 |
Sindet-Pedersen [45] | 2017 | Rivaroxaban | 5411 | 66 | 2705a | 0.5 | 2.3 | 3.0 | 5.3a | NR |
Coleman [46] | 2017 | Rivaroxaban | 13,609 | 42% > 60 | 6804a | 0.5 | 0.8 | 2.8 | 3.6a | NR |
Berger [48] | 2018 | Rivaroxaban | 3763 | 57.2 | 1656a | 0.44 | 1.1 | 1.4 | 2.5a | NR |
Weycker [47] | 2018 | Apixaban | 17,878 | 60 | 7008a | 0.4 | 4.2 | 5.8 | 10.0a | NR |